Thursday, Oct 01, 2020 | Last Update : 09:24 PM IST

189th Day Of Lockdown

Maharashtra1351153104994735751 Andhra Pradesh6811616123005745 Tamil Nadu5863975307089383 Karnataka5824584697508641 Uttar Pradesh3908753312705652 Delhi2730982407035272 West Bengal2505802198444837 Odisha212609177585866 Telangana1872111564311107 Kerala179923121264698 Bihar178882164537888 Assam169985139977655 Gujarat1332191132403417 Rajasthan1288591077181441 Haryana1237821059901307 Madhya Pradesh117588932382207 Punjab107096840253134 Chhatisgarh9856566860777 Jharkhand7770964515661 Jammu and Kashmir69832495571105 Uttarakhand4533233642555 Goa3107125071386 Puducherry2548919781494 Tripura2412717464262 Himachal Pradesh136799526152 Chandigarh112128677145 Manipur9791760263 Arunachal Pradesh8649623014 Nagaland5768469311 Meghalaya5158334343 Sikkim2707199431 Mizoram178612880
  Science   04 May 2020  Roche gets USFDA nod for coronavirus antibody test

Roche gets USFDA nod for coronavirus antibody test

REUTERS
Published : May 4, 2020, 12:34 pm IST
Updated : May 4, 2020, 12:34 pm IST

The brand claims its test relies on intravenous blood draws, which gives results with higher accuracy than finger-prick tests

 Representational Image. (AFP)
  Representational Image. (AFP)

Washington: Roche has won emergency approval from the U.S. Food and Drug Administration (FDA) for an antibody test to determine whether people have ever been infected with the coronavirus, the Swiss drugmaker on Sunday.

Thomas Schinecker, Roche’s head of diagnostics, said the company aims to more than double production of tests from about 50 million a month to significantly more than 100 million a month by the end of the year.

 

Governments, businesses and individuals are seeking such blood tests to learn who may have had the disease, who may have some immunity and to potentially craft strategies to help end national lockdowns.

Basel-based Roche, which also makes molecular tests to identify active COVID-19 infections, said its antibody test has a specificity rate exceeding 99.8% and sensitivity of 100%, meaning tests would show very few false positives and no false negatives.

A false-positive result could lead to the mistaken conclusion that someone has immunity. Roche said its test relies on intravenous blood draws, with higher accuracy than finger-prick tests.

 

“If you take blood from a finger prick, you will never be able to achieve the same level of specificity that you will achieve ... when you take blood from the vein,” Schinecker said.

“You have to have very, very high specificity. Even 0.1% or 0.2% makes a difference.”

RIVALS’ TESTS

Similar antibody tests have also been developed by companies including U.S.-based Abbott Laboratories, Becton Dickinson and Italy’s DiaSorin.

Abbott has said the specificity and sensitivity of its test are 99.5% and 100% respectively. Diasorin has said its Liason XL test has 97.4% sensitivity and 98.5% specificity.

As demand escalates for antibody tests, an array of distributors with no background or established testing competency have also joined the experienced companies in an all-but-unregulated marketplace in the United States, according to a Reuters investigation.

 

Roche did not disclose a price for its test but said that it would be identical worldwide.

Schinecker foresees a high need for testing healthcare workers and their families for exposure, and those who showed signs and symptoms, to see if they have antibodies.

While antibodies typically confer some immunity, Schinecker acknowledged that much remains to be learned about the novel coronavirus before drawing definitive conclusions.

“Since this virus is not well known, one can hypothesise, but the proof will take longer,” he said. “Testing these people ... is key to seeing whether or not people really have developed immunity.”

Tags: roche, coronavirus testing, covid-19, approval, thomas schinecker, abbott laboratories, becton dickinson, diasorin